Yann Echelard
Director/Board Member chez TG THERAPEUTICS, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Yann Echelard is an Independent Director at TG Therapeutics, Inc., a Director at LFB USA, Inc., a Director at Hema Biologics, and an Operating Partner at Flagship Pioneering.
He is also the President of Ampersand Biomedicines, Inc. Previously, he was the President, Chief Executive Officer & Director of rEVO Biologics, Inc. from 2012 to 2018.
He was also a Principal at rEVO Biologics, Inc. from 1994 to 2010.
Additionally, he was the Vice President-Research & Development at GTC Biotherapeutics UK Ltd., and the Founding President of Ring Therapeutics, Inc., Cellarity Inc., and Laronde, Inc. Dr. Echelard holds a doctorate degree from the University of Montréal.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TG THERAPEUTICS, INC.
0,14% | 28/09/2023 | 221 848 ( 0,14% ) | 3 M $ | 31/03/2024 |
Postes actifs de Yann Echelard
| Sociétés | Poste | Début |
|---|---|---|
| TG THERAPEUTICS, INC. | Director/Board Member | 09/11/2012 |
Hema Biologics
 Hema Biologics Pharmaceuticals: MajorHealth Technology Hema Biologics is a private company that aims to support patients living with rare bleeding disorders. The company is based in Louisville, KY. The company offers an interactive experience through their app, where users can become Sergeant Factor. | Director/Board Member | - |
LFB USA, Inc.
 LFB USA, Inc. Pharmaceuticals: MajorHealth Technology LFB USA, Inc. is a pharmaceutical company based in Framingham, MA. The private company develops and provides pharmaceutical bioproducts through innovative technologies for patients with serious diseases. LFB USA is committed to improving people's lives by overcoming barriers through purposeful science. The company offers a robust set of services that powers its own pipeline to its partners. LFB USA's rpro technology is revolutionizing recombinant protein production for a new generation of therapeutics. The company is ultimately controlled by the Government of France. Jose Antonio Moreno Toscano has been the CEO of the company since 2018. | Director/Board Member | - |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/10/2018 |
Ampersand Biomedicines
 Ampersand Biomedicines BiotechnologyHealth Technology Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023. | President | - |
Anciens postes connus de Yann Echelard
| Sociétés | Poste | Fin |
|---|---|---|
| REVO BIOLOGICS INC | Chief Executive Officer | 01/04/2018 |
| GTC Biotherapeutics UK Ltd. | Director/Board Member | 01/12/2010 |
| REVO BIOLOGICS INC | Corporate Officer/Principal | 01/01/2010 |
Laronde Inc.
 Laronde Inc. Miscellaneous Commercial ServicesCommercial Services Laronde Inc. is a company that aims to advance eRNA-based therapeutics through their powerful new platform called endless RNA (eRNA™). The company is based in Cambridge, MA and was founded by Noubar B. Afeyan. This platform can be programmed to make any therapeutic protein inside the body, making it the most versatile RNA platform for life-changing medicines. | Corporate Officer/Principal | - |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Yann Echelard
| University of Montréal | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
LFB USA, Inc.
LFB USA, Inc. Pharmaceuticals: MajorHealth Technology LFB USA, Inc. is a pharmaceutical company based in Framingham, MA. The private company develops and provides pharmaceutical bioproducts through innovative technologies for patients with serious diseases. LFB USA is committed to improving people's lives by overcoming barriers through purposeful science. The company offers a robust set of services that powers its own pipeline to its partners. LFB USA's rpro technology is revolutionizing recombinant protein production for a new generation of therapeutics. The company is ultimately controlled by the Government of France. Jose Antonio Moreno Toscano has been the CEO of the company since 2018. | Health Technology |
| GTC Biotherapeutics UK Ltd. | |
Hema Biologics
Hema Biologics Pharmaceuticals: MajorHealth Technology Hema Biologics is a private company that aims to support patients living with rare bleeding disorders. The company is based in Louisville, KY. The company offers an interactive experience through their app, where users can become Sergeant Factor. | Health Technology |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Laronde Inc.
Laronde Inc. Miscellaneous Commercial ServicesCommercial Services Laronde Inc. is a company that aims to advance eRNA-based therapeutics through their powerful new platform called endless RNA (eRNA™). The company is based in Cambridge, MA and was founded by Noubar B. Afeyan. This platform can be programmed to make any therapeutic protein inside the body, making it the most versatile RNA platform for life-changing medicines. | Commercial Services |
Ampersand Biomedicines
Ampersand Biomedicines BiotechnologyHealth Technology Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023. | Health Technology |
